Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

A series of disappointments that drove Sage Therapeutics Inc.’s stock down by 85% since August of 2023 has evolved into an unsolicited takeout offer by partner Biogen Inc., followed by a lawsuit filed ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on SAGE Therapeutics (SAGE – Research Report), with a ...

SAGE Therapeutics Inc (SAGE) stock saw a modest uptick, ending the day at $7.08 which represents a slight increase of $0.11 or 1.58% from the prior close of $6.97. The stock opened at $7.02 and ...

In a report released today, George Farmer from Scotiabank maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report), with a price ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal ...

Key Takeaways Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the ...

Sage stock rose 35% to $7.51 in premarket trading Monday; it closed at $5.55 on Friday. Biogen shares dipped 0.5% to $48.01.

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...